# Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

> **NCT02670616** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 24 (actual)

## Conditions studied

- Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** vincristine
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT02670616
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-01
- **Primary completion:** 2020-06
- **Final completion:** 2020-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02670616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02670616, "Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02670616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*